Safety and Efficacy of a Kaolin-Impregnated Hemostatic Gauze in Cardiac Surgery: A Randomized Trial

Authors

Mubashir Mumtaz
Richard B Thompson
Marc R Moon
Ibrahim Sultan
T Brett Reece
William B Keeling
Jacob DeLaRosa

Language

English

Publication Date

6-1-2023

Journal

JTCVS Open

DOI

10.1016/j.xjon.2023.03.016

PMID

37425449

PMCID

PMC10328980

PubMedCentral® Full Text Version

Post-print

Abstract

OBJECTIVE: A kaolin-based nonresorbable hemostatic gauze, QuikClot Control+, has demonstrated effective hemostasis and safety when used for severe/life-threatening (grade 3/4) internal organ space bleeding. We evaluated the efficacy and safety of this gauze for mild to moderate (grade 1-2) bleeding in cardiac surgery compared with control gauze.

METHODS: This was a randomized, controlled, single-blinded study of patients who underwent cardiac surgery between June 2020 and September 2021 across 7 sites with 231 subjects randomized 2:1 to QuikClot Control+ or control. The primary efficacy end point was hemostasis rate (ie, subjects achieving grade 0 bleed) through up to 10 minutes of bleeding site application, assessed using a semiquantitative validated bleeding severity scale tool. The secondary efficacy end point was the proportion of subjects achieving hemostasis at 5 and 10 minutes. Adverse events, assessed up to 30 days postsurgery, were compared between arms.

RESULTS: The predominant procedure was coronary artery bypass grafting, and 69.7% and 29.4% were sternal edge and surgical site (suture line)/other bleeds, respectively. Of the QuikClot Control+ subjects, 121 of 153 (79.1%) achieved hemostasis within 5 minutes, compared with 45 of 78 (58.4%) controls (P < .001). At 10 minutes, 137 of 153 patients (89.8%) achieved hemostasis compared with 52 of 78 controls (68.4%) (P < .001). At 5 and 10 minutes, hemostasis was achieved in 20.7% and 21.4% more QuikClot Control+ subjects, respectively, compared with controls (P < .001). There were no significant differences in safety or adverse events between treatment arms.

CONCLUSIONS: QuikClot Control+ demonstrated superior performance in achieving hemostasis for mild to moderate cardiac surgery bleeding compared with control gauze. The proportion of subjects achieving hemostasis was more than 20% higher in QuikClot Control+ subjects at both timepoints compared with controls, with no significant difference in safety outcomes.

Keywords

bleeding control, clinical trial, hemostatic device, kaolin, time to hemostasis

Published Open-Access

no

Recommended Citation

Mumtaz, Mubashir; Thompson, Richard B; Moon, Marc R; et al., "Safety and Efficacy of a Kaolin-Impregnated Hemostatic Gauze in Cardiac Surgery: A Randomized Trial" (2023). Faculty and Staff Publications. 3735.
https://digitalcommons.library.tmc.edu/baylor_docs/3735